Results: Histological distribution was as follows: 69 marginal zone lymphomas (MZL), 6 lymphoplasmacytic lymphomas, 8 follicular lymphomas, 10 CLL/small lymphocytic lymphoma (SLL), 4 low-grade NHL non otherwise specified.All but thirteen patients received a Sofosbuvir-based regimen.Median duration of DAA therapy was 12 weeks (range 4-24 weeks).A sustained virological response at week 12 after finishing DAAs (regarded as cure of HCV) was obtained in 99% of patients; overall LDR rate was 73% including 29 patients (30%) achieving a complete response and 41 (43%), a partial response.After a median follow up of 15 months, 2-year progression-free and overall survival were 70% [95% confidence interval: 49% -83%] and 97% [88-99%], respectively.Conclusions: DAA therapy induces a high LDR rate in HCV-associated lymphoproliferative disorders and confirms the role of HCV in lymphomagenesis.This chemotherapy-free approach should be considered first-line therapy in patients without need of urgent treatment.Prospective trials are eagerly awaited in this setting.
No takes yet. Share an insight, caveat, or question.
Herold et al. (2017) studied this question.